September 10, 2007
Takeda Pharmaceutical announced on August 30 that its investigational compound TAK-536 has entered the PII clinical stage in Japan. TAK-536 is a new angiotensin receptor blocker (ARB) discovered by Takeda. It is expected to show stronger anti-hypertensive action, and also...read more